Ciclo celular/Ponto de verificação
Os inibidores do ciclo celular/ponto de verificação são compostos que interrompem a progressão normal do ciclo celular, particularmente em pontos de verificação regulatórios chave. Esses inibidores são cruciais para estudar a divisão celular, entender a proliferação de células cancerígenas e desenvolver terapias anticâncer. Ao direcionar fases específicas do ciclo celular, esses inibidores podem induzir a parada do ciclo celular, levando à apoptose ou senescência em células de divisão rápida. Na CymitQuimica, oferecemos uma ampla gama de inibidores de alta qualidade do ciclo celular/ponto de verificação para apoiar sua pesquisa em biologia do câncer, biologia celular e desenvolvimento de medicamentos.
Subcategorias de "Ciclo celular/Ponto de verificação"
- Aurora Quinase(111 produtos)
- CDK(522 produtos)
- Ciclo celular/Parada(4 produtos)
- Chk(46 produtos)
- DYRK(49 produtos)
- Dinamina(26 produtos)
- Ferroptose(225 produtos)
- HSP(180 produtos)
- Integrinas(256 produtos)
- Cinesina(85 produtos)
- LIM Quinase(19 produtos)
- Microtúbulo associado(285 produtos)
- PKC(111 produtos)
- PLK(25 produtos)
- ROCK(67 produtos)
- Rho(2 produtos)
- Wee1(14 produtos)
- c-Myc(75 produtos)
Exibir 10 mais subcategorias
Foram encontrados 3739 produtos de "Ciclo celular/Ponto de verificação"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
IIP0943
CAS:IIP0943 is a selective PLK1 (polo-like kinase 1) inhibitor with an IC50 of 5.1 nM for PLK1. It also exhibits inhibitory activity on the proliferation of HCT116 cells, with an IC50 of 0.22 µM. IIP0943 shows potential for research in the field of oncology.Fórmula:C26H28N6O3SCor e Forma:SolidPeso molecular:504.604RECTAS-2.0
CAS:<p>RECTAS-2.0 is a small molecule designed to correct RNA mis-splicing caused by the GLA c.639+919G>A mutation, intended for research in Fabry disease.</p>Fórmula:C18H17ClN4O4Cor e Forma:SolidPeso molecular:388.805RMS-07
CAS:RMS-07, a covalent MPS1/TTK inhibitor, has an IC50 of 13.1 nM, targeting a kinase hinge cysteine.Fórmula:C35H40N8O2Cor e Forma:SolidPeso molecular:604.74WEE1/PKMYT1-IN-1
CAS:<p>WEE1/PKMYT1-IN-1 (compound 75) is an effective and orally bioavailable inhibitor of WEE1 and PKMYT1. It demonstrates antiproliferative activity.</p>Fórmula:C16H16N4O3Cor e Forma:SolidPeso molecular:312.3235-Iminodaunorubicin hydrochloride
CAS:<p>5-Iminodaunorubicin HCl: quinone-modified anthracycline with antitumor properties, induces DNA breaks in cancer cells.</p>Fórmula:C27H31ClN2O9Cor e Forma:SolidPeso molecular:563.00PCNA-IN-1
CAS:PCNA-IN-1 (Compound 11) is an inhibitor of the PCNA/PIP-box interaction, with an IC50 greater than 50 μM. It is applicable in cancer research.Fórmula:C19H18I3NO3Cor e Forma:SolidPeso molecular:689.065RAD51-IN-7
CAS:RAD51-IN-7 inhibits RAD51 gene, with potential for mitochondrial disorders. (From WO2021164746A1, cmpd 71)Fórmula:C25H31N5O4S2Cor e Forma:SolidPeso molecular:529.67T-2513 hydrochloride
CAS:T-2513 hydrochloride: selective topoisomerase I inhibitor, binds DNA complex, halts DNA/RNA synthesis, causes cell death.Fórmula:C25H28ClN3O5Cor e Forma:SolidPeso molecular:485.962-CEES
CAS:2-CEES is a mustard gas analogue that only forms DNA monoadducts. It induces centromere amplification in both human and mouse cells and can lead to chromosome instability.Fórmula:C4H9ClSCor e Forma:SolidPeso molecular:124.632Dyrk1A-IN-2
Dyrk1A-IN-2 is a DYRK1A inhibitor (EC50: 37 nM). dyrk1A-IN-2 exhibits efficient promotion of human β-cell replication, as well as low cytotoxicity.Fórmula:C27H32N6O4Cor e Forma:SolidPeso molecular:504.58DDO-6079
CAS:DDO-6079 is an efficient CDC37 inhibitor. It suppresses the HSP90-CDC37 and CDC37-CDK4/6 chaperone complexes by binding to an allosteric site on CDC37. Additionally, DDO-6079 reduces the thermal stability of CDK6.Fórmula:C18H13ClN2O3Cor e Forma:SolidPeso molecular:340.76Cdc7-IN-10
CAS:Cdc7-IN-10 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in studies of proliferative diseases.Fórmula:C20H22F2N4O2SCor e Forma:SolidPeso molecular:420.48Z4P
CAS:Z4P, an IRE1 inhibitor with blood-brain barrier permeability (BBB), inhibited glioblastoma growth and recurrence in combination with Temozolomide.Fórmula:C19H24N2O2Pureza:98.99%Cor e Forma:SolidPeso molecular:312.41WEE1-IN-10
CAS:WEE1-IN-10 is a Wee1 kinase inhibitor that inhibits the growth of LOVO cells, such as pancreatic cancer, malignant melanoma, and malignant glioma.Fórmula:C28H30Cl2N8OPureza:98.18%Cor e Forma:SolidPeso molecular:565.5Terpendole E
CAS:Terpendole E is an atypical L5 site inhibitor.Fórmula:C28H39NO3Cor e Forma:SolidPeso molecular:437.612-Amino-2'-fluoro-2'-deoxyadenosine
CAS:<p>2-Amino-2'-fluoro-2'-deoxyadenosine is a component of nucleic acids.</p>Fórmula:C10H13FN6O3Cor e Forma:SolidPeso molecular:284.25Glycyl H-1152 hydrochloride
CAS:Glycyl-H-1152 is a potent ROCK-II inhibitor (IC50=11.8 nM) with high selectivity over CaMKII, PKG, Aurora A, PKA, and PKC. Better than Y-27632 and HA-1077.Fórmula:C18H26Cl2N4O3SCor e Forma:SolidPeso molecular:449.39Haspin-IN-2
CAS:<p>Haspin-IN-2 is a potent haspin inhibitor (IC50: 50 nM) and also inhibits CLK1 (IC50: 445 nM) and DYRK1A (IC50: 917 nM).</p>Fórmula:C12H8N4O3Cor e Forma:SolidPeso molecular:256.22KL-50
CAS:KL-50, a selective toxin, effectively targets tumors deficient in the DNA repair protein O6-methylguanine-DNA-methyltransferase (MGMT), which corrects O6-alkylguanine lesions. This compound induces both DNA damage response pathways and cell cycle arrest in MGMT-deficient cells, regardless of mismatch repair (MMR) status. KL-50 shows promise in the study of brain tumors lacking MGMT.Fórmula:C7H7FN6O2Cor e Forma:SolidPeso molecular:226.17Aurora/LIM kinase-IN-1
Aurora/LIM kinase-IN-1 (Compound F114) is a dual inhibitor targeting aurora and lim kinases, potentially useful in GBM cancer treatment efforts.Fórmula:C16H20N6OCor e Forma:SolidPeso molecular:312.37Cdc7-IN-8
CAS:Cdc7-IN-8, inhibits Cdc7 kinase, key in DNA replication, and is promising for cancer research. (WO2021032170A1)Fórmula:C19H21N5O2Cor e Forma:SolidPeso molecular:351.403′-Amino-2′,3′-dideoxy-CTP
CAS:3′-Amino-2′,3′-dideoxy-CTP is an analog of nucleoside triphosphates. It selectively inhibits DNA polymerase β.Fórmula:C9H17N4O12P3Cor e Forma:SolidPeso molecular:466.17APE1-IN-3
CAS:<p>APE1-IN-3 (Compound 1), an APE1 inhibitor, is utilized in cancer research.</p>Fórmula:C17H16O4Cor e Forma:SolidPeso molecular:284.31PKMYT1-IN-2
CAS:PKMYT1-IN-2 (compound 2) serves as a powerful inhibitor of PKMYT1, exhibiting an IC 50 of 5.7 nM. Additionally, it effectively suppresses the proliferation of HCC1569 cells with an IC 50 of 22 nM [1].Fórmula:C22H19N5O2Cor e Forma:SolidPeso molecular:385.42L-I-OddU
CAS:<p>L-I-OddU: Selective anti-EBV, halts virus DNA/protein synthesis. EC50: 0.03 µM, low toxicity (CC50: 1000 nM).</p>Fórmula:C8H9IN2O5Cor e Forma:SolidPeso molecular:340.07CDK7-IN-17
CAS:CDK7-IN-17, a pyrimidine-based CDK7 inhibitor, shows promise for various cancers, especially with abnormal transcription.Fórmula:C24H26F3N6OPPureza:99.60%Cor e Forma:SolidPeso molecular:502.473-deoxy-3-fluoro-β-D-Ribofuranose 25
CAS:Compound 25, β-D-Ribofuranose, 3-deoxy-3-fluoro-, 1,2-diacetate 5-(4-methylbenzoate), exhibits strong activity in inhibiting the growth of tumor cells [1].Fórmula:C17H19FO7Peso molecular:354.33TASIN-30
CAS:<p>TASIN-30 is an inhibitor of EBP, exhibiting a competitive EC50 value of 0.097 μM, and possesses a competitive EC50 value of 50 μM against DHCR7.</p>Fórmula:C18H30N2O3SCor e Forma:SolidPeso molecular:354.51CDK7/12-IN-1
CAS:CDK7/12-IN-1 is a selective CDK7 (IC50: 3 nM) and CDK12 (IC50: 277 nM) inhibitor, effective against tumor growth.Fórmula:C25H34N8OCor e Forma:SolidPeso molecular:462.59Kolavenic acid analog
CAS:KAA, an anticancer compound, inhibits centrosome clustering and targets HSET+ yeast and cancer cells.Fórmula:C25H38O4Cor e Forma:SolidPeso molecular:402.57DS96432529
DS96432529 is a potent and orally active bone anabolic agent through CDK8 inhibition.Fórmula:C18H26N4O3SCor e Forma:SoildPeso molecular:378.49Antimalarial agent 44
Antimalarial agent 44 (Compound 3) is an antiparasitic agent effective against malaria. It exhibits good permeability in MDCK-MDR1 cell monolayers and has a high clearance rate in mouse liver microsomes.Fórmula:C37H37N5O7Cor e Forma:SolidPeso molecular:663.72CHK1 inhibitor
CAS:CHK1 inhibitor (GDC-0575 analog) is a CHK1 inhibitor.Fórmula:C17H21BrN4OPureza:98%Cor e Forma:SolidPeso molecular:377.28PD-1-IN-17
CAS:PD-1-IN-17 is an inhibitor of programmed cell death-1 (PD-1). PD-1-IN-17 inhibits 92% splenocyte proliferation at 100 nM.Fórmula:C13H22N6O7Pureza:99.6%Cor e Forma:SolidPeso molecular:374.35Aurora A inhibitor 4
CAS:Aurora A inhibitor4 (compound C9) is a potent inhibitor of Aurora A, with GI50 values of 4.26 μM in DU 145 cells and 7.08 μM in HT-29 cells.Fórmula:C22H23N5O3Peso molecular:405.45D-G23
CAS:<p>D-G23 is a selective RAD52 inhibitor. It disrupts RAD52-mediated DNA repair pathways and suppresses the growth of cancer cells deficient in BRCA1 and BRCA2. D-G23 shows promise for research into homologous recombination-related cancers caused by BRCA1/2 mutations, such as hereditary breast and ovarian cancers.</p>Fórmula:C19H22N4O3Cor e Forma:SolidPeso molecular:354.403Antibacterial agent 110
Compound 4e, an antibacterial against P. aeruginosa, disrupts cell membranes (MIC: 1 μg/ml).Fórmula:C22H21N5O4SCor e Forma:SolidPeso molecular:451.5LIMK1 inhibitor 2
CAS:LIMK1 inhibitor 2 (compound 41) is a LIMK1 inhibitor with an IC50 value of 9 μM.Fórmula:C10H11N3OSCor e Forma:SolidPeso molecular:221.279Norharmine
CAS:Norharmine is an analogue of harman and functions as an alkaloid. It serves as an inhibitor of both monoamine oxidase A (MAO-A) and DYRK1A. While it exhibits weak inhibitory activity against MAO-A, it has certain inhibitory effects on DYRK1A.Fórmula:C12H10N2OCor e Forma:SolidPeso molecular:198.2215-Fluorouridine 5'-phosphate
CAS:5-Fluorouridine 5'-phosphate acts as an ODCase (uridine 5'-monophosphate decarboxylase) inhibitor, exhibiting a Ki value of 98 µM for human ODCase and 645 µM for Methanococcus jannaschii ODCase. This compound also shows inhibitory activity on leukemia and lymphoma cell lines, making it useful for cancer research studies.Fórmula:C9H12FN2O9PCor e Forma:SolidPeso molecular:342.172Protein kinase inhibitor 14
CAS:Protein kinase inhibitor 14 (Compound 13) exhibits inhibitory effects on various serine/threonine kinases and receptor/non-receptor tyrosine kinases.Fórmula:C22H22F2N6OPeso molecular:424.447Cdc7-IN-11
CAS:Cdc7-IN-11 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in the study of proliferative diseases.Fórmula:C20H22F2N4O2SCor e Forma:SolidPeso molecular:420.48Y-99
CAS:Y-99 is a PORCN inhibitor with an IC50 value of 155.4 nM for suppressing the Wnt/β-catenin signaling pathway. Additionally, Y-99 inhibits the expression of p-LRP6, β-catenin, and c-Myc.Fórmula:C18H17F2N5O3Cor e Forma:SolidPeso molecular:389.36Tetrahydrouridine dihydrate
THU dihydrate, a potent CDA inhibitor, outperforms cytidine by blocking the enzyme's active site.Fórmula:C9H20N2O8Cor e Forma:SolidPeso molecular:284.26BAY-364
CAS:BAY-364 (BAY-299N) functions as an inhibitor targeting the second bromine domain in TAF1, demonstrating inhibitory effects on TAF1 in Kasumi-1 cells, CD34+Fórmula:C23H19N3O4Cor e Forma:SolidPeso molecular:401.41Anti-neuroinflammation agent 3
CAS:Compound A.10.3 (Anti-neuroinflammation agent 3) exhibits inhibitory activity against various Ser/Thr kinases or receptor/non-receptor tyrosine kinases.Fórmula:C22H23FN6O2Peso molecular:422.455MtTMPK-IN-2
CAS:MtTMPK-IN-2 inhibits M. tuberculosis TMPK (IC50: 1.1 μM), Mtb H37Rv (MIC: 12.5 μM), and is cytotoxic in MRC-5 cells (EC50: 6.1 μM).Fórmula:C23H24ClN3O3Cor e Forma:SolidPeso molecular:425.91CDK7-IN-33
CAS:CDK7-IN-33 (Compound 148) is a CDK7 inhibitor with a Ki value of 21.75 nM. It suppresses the proliferation of A549 cells expressing CDK7WT, with a pIC50 of 7.37.Fórmula:C29H36N6O4SCor e Forma:SolidPeso molecular:564.699Polθ-IN-8
CAS:Polθ-IN-8 (example 77) is a DNA polymerase θ (Polθ) inhibitor with an IC50 for Polθ ATPase activity of less than 100 nM. Polθ-IN-8 is useful for researching diseases related to Polθ activity, such as cancer.Fórmula:C22H22ClN7O3SCor e Forma:SolidPeso molecular:499.97MtTMPK-IN-1
MtTMPK-IN-1 inhibits MtTMPK with 2.5 μM IC50, shows moderate anti-tuberculosis activity, and is low in cytotoxicity.Fórmula:C22H24N4O3Cor e Forma:SolidPeso molecular:392.45PT109
CAS:PT109 is a multikinase inhibitor that targets JNK and other kinases, playing a crucial role in anti-inflammatory, antioxidative, neurogenic, and synaptogenic processes. Specifically, PT109 inhibits JNK isoforms with the following IC50 values: JNK1 at 0.143 μM, JNK2 at 0.831 μM, and JNK3 at 0.285 μM. It also inhibits SGK isoforms (SGK1: IC50=1.34 μM; SGK2: IC50=5.6 μM; SGK3: IC50=26.4 μM) and ROCK2 (IC50=34 μM). Additionally, PT109 reprograms polymorphic glioblastoma multiforme (GBM) into oligodendroglia via the PTBP1/PKM1/2 pathway and alters the metabolic pattern of GBM to exhibit antiglioma activity.Fórmula:C23H31N3OS2Cor e Forma:SolidPeso molecular:429.645'-O-Dmt-n2-isobutyryl-2'-o-methyl-d-guanosine
CAS:5'-O-Dmt-n2-isobutyryl-2'-o-methyl-d-guanosine is a nucleoside synthesized through oxime ring-opening at the 5' position and methylation at the 2' position. In chemotaxis assays, 5'-O-Dmt-n2-isobutyryl-2'-o-methyl-d-guanosine demonstrates tissue affinity.Fórmula:C36H39N5O8Cor e Forma:SolidPeso molecular:669.724CDK7-IN-26
CAS:CDK7-IN-26 (compound 36) is an orally active CDK7 inhibitor with an IC50 of 7.4 nM. The compound effectively suppresses the growth of xenograft tumors derived from triple-negative breast cancer (TNBC) cell lines in vivo and has an IC50 of 0.15 μM for inhibiting MDA-MB-453 cells in vitro.Fórmula:C22H22FN6OPSPeso molecular:468.49CDK2-IN-18
CAS:<p>CDK2-IN-18 (compound 8q) serves as a powerful inhibitor of CDK 2/E and CDK 4/D1, showing IC50 values of 8 nM and 46 nM, respectively. It effectively inhibits tumor cell proliferation [1].</p>Fórmula:C21H23N7O2SCor e Forma:SolidPeso molecular:437.52Dencatistat
CAS:<p>Dencatistat is a highly selective and oral cytidine triphosphate synthase 1 CTPS1 inhibitor specific.CTPS1-IN-2 for B-cell, T-cell lymphomas and solid tumors.</p>Fórmula:C24H27N7O5SPureza:98.85%Cor e Forma:SolidPeso molecular:525.58ART615
ART615 is a related isomer of ART558. ART615 inhibits Polθ by <10% at 12 μM and is able to act as a control for ART558 (IC50:7.9 nM).Fórmula:C21H21F3N4O2Cor e Forma:SolidPeso molecular:418.41CLK1/4-IN-1
CLK1/4-IN-1 inhibits Clk1/4 (IC50: 9.7/6.6 nM), curbing T24 cell growth (GI50: 1.1 μM). Potential cancer research tool.Fórmula:C18H14ClNO4SCor e Forma:SolidPeso molecular:375.83Antitumor agent-74
Antitumor agent-74, a quinazoline derivative, inhibits DNA, arrests cell cycle, and induces apoptosis with agent-75.Fórmula:C26H23FN6Cor e Forma:SolidPeso molecular:438.5Antiviral agent 67
CAS:Antiviralagent 67 (compound PC6) is an inhibitor of DENVNS5 (RNA-dependent RNA polymerase) with a Ki value of 1.12 nM.Fórmula:C19H19N3OCor e Forma:SolidPeso molecular:305.374GSK_WRN4
CAS:<p>GSK_WRN4 is a WRN helicase inhibitor with anti-cancer activity, inhibiting MSI tumor cell growth by inducing DNA double-strand breaks, useful in cancer research</p>Fórmula:C16H20N2O4SPureza:99.95%Cor e Forma:SolidPeso molecular:336.41UMPK ligand 1
CAS:<p>UMPK ligand 1 (ZINC07785412) serves as a ligand for uridine monophosphate kinase (UMPK).</p>Fórmula:C15H22N4O5SCor e Forma:SolidPeso molecular:370.4242′-OMe-UDP
CAS:2′-OMe-UDP is a nucleotide analog utilized in the synthesis of oligonucleotides.Fórmula:C10H16N2O12P2Cor e Forma:SolidPeso molecular:418.19CDK9-IN-13
<p>CDK9-IN-13 is a potent and selective CDK inhibitor (IC50<3 nM). CDK9-IN-13 has a very short half-life in rodents.</p>Fórmula:C27H35N5O2Cor e Forma:SolidPeso molecular:461.6DYRKs-IN-1 hydrochloride
CAS:DYRKs-IN-1 HCl inhibits DYRK1A (5 nM IC50) & DYRK1B (8 nM IC50) with antitumor properties.Fórmula:C30H31Cl2N7O4Cor e Forma:SolidPeso molecular:624.52Uridine 3',5'-diphosphate
CAS:<p>Uridine 3′,5′-diphosphate (3′,5′-UDP; Compound pUp) serves as a competitive RNase inhibitor [1].</p>Fórmula:C9H14N2O12P2Cor e Forma:SolidPeso molecular:404.164,5'-Dimethylangelicin-NHS
NHS-modified coumarin, 4,5'-Dimethylangelicin-NHS, shows photochemical activity & photosensitivity.Fórmula:C21H19NO7SCor e Forma:SolidPeso molecular:429.44MtTMPK-IN-9
MtTMPK-IN-9 moderately inhibits MtbTMPK (IC50: 48 μM), has submicromolar Mycobacterium activity, and is non-toxic, aiding tuberculosis research.Fórmula:C25H26N6O7Cor e Forma:SolidPeso molecular:522.51Aurora inhibitor 1
CAS:<p>Aurora inhibitor 1 is a potent Aurora inhibitor (IC50: ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase).</p>Fórmula:C23H25N9SPureza:98%Cor e Forma:SolidPeso molecular:459.572′-F-UDP
CAS:2′-F-UDP is a nucleotide analogue used in the synthesis of oligonucleotides.Fórmula:C9H13FN2O11P2Cor e Forma:SolidPeso molecular:406.15Antiangiogenic agent 2
<p>Antiangiogenic agent 2 (compound 3b) is a potent inhibitor of thymidine phosphorylase (IC50: 39.71 μM) and exhibits anti-angiogenic effects.</p>Fórmula:C26H26FN3O4Cor e Forma:SolidPeso molecular:463.5Ascofuranone
CAS:Ascofuranone is an inhibitor of the ubiquinol oxidase activity of Trypanosoma brucei mitochondrial alternative oxidase (TAO), as well as an inhibitor of HsDHODHFórmula:C23H29ClO5Cor e Forma:SolidPeso molecular:420.93RAD51-IN-6
CAS:RAD51-IN-6, a potent RAD51 gene inhibitor, may help research mitochondrial disorders. (WO2021164746A1, cmpd 23)Fórmula:C27H40N3O5PSCor e Forma:SolidPeso molecular:549.66MtTMPK-IN-8
<p>MtTMPK-IN-8 inhibits MtbTMPK, has low cytotoxicity, shows 0.78-9.4 μM activity against Mycobacterium, useful for tuberculosis research.</p>Fórmula:C24H24N6O7Cor e Forma:SolidPeso molecular:508.48CDK4/6-IN-3
CAS:CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM.Fórmula:C25H31FN8Pureza:98%Cor e Forma:SolidPeso molecular:462.57LIMK1 inhibitor 1
CAS:LIMK1 inhibitor1 (compound 24) is a LIMK1 inhibitor, potentially useful for cancer research.Fórmula:C12H15N3S2Cor e Forma:SolidPeso molecular:265.398UM-C162
CAS:UM-C162, a benzimidazole derivative, offers protection to nematodes from Staphylococcus aureus infections. It inhibits biofilm formation without impairing bacterial viability. Additionally, UM-C162 disrupts the production of Staphylococcus aureus hemolysins, proteases, and coagulases. This compound holds potential as an antivirulence agent for managing Staphylococcus aureus infections.Fórmula:C30H25N3O4Peso molecular:491.54CDK1-IN-3
CDK1-IN-3 is a selective inhibitor targeting CDK1 (36.8 nM), CDK2 (305.17 nM), CDK5 (369.37 nM); used in cancer research.Fórmula:C28H25ClF3N5O2Cor e Forma:SolidPeso molecular:555.982′-OMe-UMP
CAS:2′-OMe-UMP is a nucleotide analog used in the synthesis of oligonucleotides.Fórmula:C10H15N2O9PPeso molecular:338.21CDK/HDAC-IN-1
CDK/HDAC-IN-1 inhibits CDK2/4/6 & HDAC6 with IC50s: 60.9, 276, 27.2, and 128.6 nM respectively.Fórmula:C20H18N4O4Cor e Forma:SolidPeso molecular:378.38c-Myc inhibitor 4
Potent oral c-Myc inhibitor 4 reduces the proto-oncogene linked to tumor development.Fórmula:C26H33FN6O3Cor e Forma:SolidPeso molecular:496.58AR-13324 M1 metabolite
CAS:<p>AR-13324 M1 metabolite is a hydrolysis metabolite of AR-13324 mesylate.</p>Fórmula:C19H19N3O2Pureza:98%Cor e Forma:SolidPeso molecular:321.37CDK8-IN-9
<p>CDK8-IN-9, potent CDK8 inhibitor (IC50: 48.6 nM), curbs tumor growth, useful for colorectal cancer research.</p>Cor e Forma:SolidDyrk1A/α-synuclein-IN-1
Dyrk1A/α-synuclein-IN-1 (Compound b1) is a dual inhibitor of Dyrk1A (IC50: 177 nM) and α-synuclein aggregation (IC50: 10.5 μM).Fórmula:C20H21N5O3SCor e Forma:SolidPeso molecular:411.48PARG-IN-7
CAS:PARG-IN-7 (Example 38) is a Poly ADP-ribose glycohydrolase (PARG) inhibitor with an IC50 of less than 0.1 μM. It reduces the viability of HCC1806-XRCC1 knockdown (KD) cells, exhibiting an IC50 of less than 1 μM. PARG-IN-7 is applicable in cancer research.Fórmula:C22H24F2N8O3S2Cor e Forma:SolidPeso molecular:550.61Adafosbuvir
CAS:Adafosbuvir has antiviral activity.Fórmula:C22H29FN3O10PCor e Forma:SolidPeso molecular:545.457CDK8-IN-5
CAS:CDK8-IN-5: potent CDK8 inhibitor, IC50=72 nM, boosts IL-10 by 43%, may aid inflammatory bowel disease research.Fórmula:C26H22N2O4Cor e Forma:SolidPeso molecular:426.46PROTAC CDK12/13 Degrader-1
PROTAC CDK12/13 Degrader-1 (7f) selectively degrades CDK12/13 at nanomolar potency, targeting breast cancer.Cor e Forma:SolidDHX9-IN-9
CAS:<p>DHX9-IN-9 (509) acts as an inhibitor of the RNA helicase DHX9, demonstrating an EC50 of 0.0177 μM in DHX9 cellular target engagement, primarily utilized in cancer research [1].</p>Fórmula:C21H21ClFN5O3S2Cor e Forma:SolidPeso molecular:510Zorubicin
CAS:<p>Zorubicin, a Daunorubicin derivative, targets topoisomerase II, inhibits DNA polymerase, and researches acute leukemia, sarcomas.</p>Fórmula:C34H35N3O10Cor e Forma:SolidPeso molecular:645.66LNA-AMP
CAS:LNA-AMP is a nucleotide analog used in the synthesis of oligonucleotides.Fórmula:C11H14N5O7PCor e Forma:SolidPeso molecular:359.23RAD51-IN-5
CAS:RAD51-IN-5 blocks RAD51; may aid mitochondrial disorder research. (WO2021164746A1, cmpd 3)Fórmula:C26H38N4O5S2Cor e Forma:SolidPeso molecular:550.73CHK-IN-1
CAS:CHK-IN-1 is a dual inhibitor of CHK1 and CHK2 with antiproliferative activity.Fórmula:C18H19ClFN5OSPureza:>99.99%Cor e Forma:SolidPeso molecular:407.89MtTMPK-IN-5
<p>MtTMPK-IN-5 inhibits Mtb TMPK with IC50 of 34 μM and fights tuberculosis with MIC of 12.5 μM, aiding TB research.</p>Fórmula:C21H23N5O2Cor e Forma:SolidPeso molecular:377.44EFdA-TP tetrasodium
CAS:EFdA-TP tetrasodium is a potent HIV-1 inhibitor that blocks DNA synthesis as an ICT or DCT.Fórmula:C12H11FN5Na4O12P3Pureza:98%Cor e Forma:SolidPeso molecular:621.12CDK7-IN-18
CAS:CDK7-IN-18: potent, pyrimidine-based CDK7 inhibitor with cancer research potential.Fórmula:C22H24F3N7OSPureza:99.28%Cor e Forma:SolidPeso molecular:491.53CDK1-IN-4
CDK1-IN-4 inhibits CDK1 (IC50: 44.52 nM), CDK2/CDK5 less potently, impacts cell cycle, used in cancer studies.Fórmula:C26H24ClN5SCor e Forma:SolidPeso molecular:474.02ATIC-IN-2
CAS:<p>ATIC-IN-2 (Compound 1) is a competitive inhibitor of the bifunctional enzyme AICAR Tfase/IMPCH (ATIC), binding to inosine monophosphate cyclohydrolase (IMPCH) with a Ki of 0.13 μM.</p>Fórmula:C4H4N4O3SCor e Forma:SolidPeso molecular:188.165CTX-712
CAS:<p>CTX-712 is a potent inhibitor of cdc2-like kinase ( CLK ). CTX-712 inhibits inhibits cancer survival and cancer cell growth.</p>Fórmula:C19H17FN8O2Cor e Forma:SolidPeso molecular:408.39PAIR2
CAS:PAIR2 is a selective IRE1α RNase partial antagonist, blocking its ATP site and preventing KIRA from hindering XBP1 splicing.Fórmula:C27H26F4N6O3SCor e Forma:SolidPeso molecular:590.59CDK12/13 ligand 1
CAS:ALK-IN-29 (compound 4c) exhibits notable inhibitory activity against tyrosine kinases such as ALK, CDK2/CyclinE1, and FAK, with the strongest inhibition observed against ALK kinase, showing a 40.63% inhibition rate at a concentration of 10 μM. ALK-IN-29 is useful for cancer research.Fórmula:C26H26BrN5OCor e Forma:SolidPeso molecular:504.42
